SHAREHOLDER ALERT: VRM KRMD FGEN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / May 10, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Vroom, Inc. (NASDAQ:VRM)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/vroom-inc-loss-submission-form?prid=15635&wire=1
Lead Plaintiff Deadline: May 21, 2021
Class Period: June 9, 2020 - March 3, 2021

Allegations against VRM include that: (1) Vroom had not demonstrated that it was able to control and scale growth in respect to its salesforce to meet the demand for its products; (2) as a result, the Company was forced to discount aged inventory to move through its retail channels or liquidated in its wholesale channels; (3) as a result, the ecommerce gross profit per unit was reasonably likely to decline; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Repro Med Systems, Inc. (NASDAQ:KRMD)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/repro-med-systems-inc-loss-submission-form?prid=15635&wire=1
Lead Plaintiff Deadline: May 25, 2021
Class Period: August 4, 2020 - January 25, 2021

Allegations against KRMD include that: (1) starting in January 2020, Repro Med Systems ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company's net sales were reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

FibroGen, Inc. (NASDAQ:FGEN)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15635&wire=1
Lead Plaintiff Deadline: June 11, 2021
Class Period: October 18, 2017 - April 6, 2021

Allegations against FGEN include that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com:
https://www.accesswire.com/646212/SHAREHOLDER-ALERT-VRM-KRMD-FGEN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines